PT2374472T - Composições e métodos para o tratamento de afeções oftalmológicas - Google Patents

Composições e métodos para o tratamento de afeções oftalmológicas

Info

Publication number
PT2374472T
PT2374472T PT111522041T PT11152204T PT2374472T PT 2374472 T PT2374472 T PT 2374472T PT 111522041 T PT111522041 T PT 111522041T PT 11152204 T PT11152204 T PT 11152204T PT 2374472 T PT2374472 T PT 2374472T
Authority
PT
Portugal
Prior art keywords
compositions
methods
ophthalmic disorders
treating ophthalmic
treating
Prior art date
Application number
PT111522041T
Other languages
English (en)
Inventor
Belichard Pierre
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of PT2374472T publication Critical patent/PT2374472T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
PT111522041T 2006-03-16 2007-03-13 Composições e métodos para o tratamento de afeções oftalmológicas PT2374472T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360008 2006-03-16
EP06291516 2006-09-26

Publications (1)

Publication Number Publication Date
PT2374472T true PT2374472T (pt) 2018-08-08

Family

ID=38292592

Family Applications (2)

Application Number Title Priority Date Filing Date
PT111522041T PT2374472T (pt) 2006-03-16 2007-03-13 Composições e métodos para o tratamento de afeções oftalmológicas
PT70051826T PT1854477T (pt) 2006-03-16 2007-03-13 Inibidores peptidicos da calicreína plasmática e sua utilização no tratamento de doenças oftalmológicas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT70051826T PT1854477T (pt) 2006-03-16 2007-03-13 Inibidores peptidicos da calicreína plasmática e sua utilização no tratamento de doenças oftalmológicas

Country Status (12)

Country Link
US (3) US20070270344A1 (pt)
JP (2) JP5337493B2 (pt)
AU (1) AU2007224643B2 (pt)
CA (1) CA2646285C (pt)
DK (1) DK1854477T3 (pt)
ES (2) ES2682646T3 (pt)
HU (2) HUE031701T2 (pt)
LT (2) LT2374472T (pt)
PL (1) PL1854477T3 (pt)
PT (2) PT2374472T (pt)
SI (1) SI2374472T1 (pt)
WO (1) WO2007104541A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT2311432E (pt) 2002-06-07 2015-02-09 Dyax Corp Polipeptídeos de domínio kunitz modificado e sua utilização para a redução de isquemia ou aparecimento de uma resposta inflamatória sistémica associada a um procedimento cirúrgico
JP4739207B2 (ja) * 2003-08-29 2011-08-03 ダイアックス コーポレーション ポリペグ化されたプロテアーゼインヒビター
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
CA2635588C (en) 2005-12-30 2015-11-10 Dyax Corp. Metalloproteinase binding proteins
DK1854477T3 (en) 2006-03-16 2016-11-28 Dyax Corp Peptide inhibitors of plasma kallikrein for use in the treatment of eye disorders
WO2008091692A2 (en) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
JP2011506614A (ja) 2007-12-17 2011-03-03 ダイアックス コーポレーション Ｍｍｐ−１４結合タンパク質を含む、骨溶解性障害を処置するための組成物および方法
EP2350305A4 (en) * 2008-10-22 2013-03-06 Dyax Corp COMBINATION TREATMENTS WITH PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISEASES
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CA3021759A1 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2013059439A2 (en) 2011-10-21 2013-04-25 Dyax Corp. Combination therapy comprising an mmp-14 binding protein
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
IL292121B2 (en) 2013-03-15 2024-02-01 Takeda Pharmaceuticals Co Anti-plasma kallikrein antibodies
WO2015063465A2 (en) 2013-10-28 2015-05-07 Bicycle Therapeutics Limited Novel polypeptides
ES2856076T3 (es) 2014-01-21 2021-09-27 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario
IL295414A (en) * 2014-03-27 2022-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema as a result of diabetes
WO2017087018A1 (en) * 2015-11-18 2017-05-26 University Of Louisville Research Foundation, Inc. Automated methods for the objective quantification of retinal characteristics by retinal region and diagnosis of retinal pathology
RU2622031C1 (ru) * 2015-12-07 2017-06-08 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения РФ Способ комбинированного лечения макулярного отека сетчатки
JP7003354B2 (ja) 2015-12-11 2022-03-04 武田薬品工業株式会社 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
GB201522441D0 (en) * 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
AU2020273154A1 (en) * 2019-04-08 2021-12-02 Biocryst Pharmaceuticals, Inc. Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
LT6899B (lt) * 2020-08-27 2022-04-11 Valstybinis mokslinių tyrimų institutas Fizinių ir technologijos mokslų centras Vario paviršiaus cheminio nikeliavimo būdas, nenaudojant aktyvavimo paladžiu
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE277081T1 (de) * 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
DK0739355T3 (da) * 1994-01-11 2005-01-24 Dyax Corp Kallikrein-inhiberende "Kunitz-domæne"-proteiner og analoger deraf
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
DE10060653A1 (de) * 2000-12-06 2002-06-20 Epcos Ag Elektrischer Doppelschicht-Kondensator
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
CA2485064A1 (en) 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused kunitz domain peptides
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT2311432E (pt) * 2002-06-07 2015-02-09 Dyax Corp Polipeptídeos de domínio kunitz modificado e sua utilização para a redução de isquemia ou aparecimento de uma resposta inflamatória sistémica associada a um procedimento cirúrgico
ES2395014T3 (es) * 2002-08-28 2013-02-07 Dyax Corp. Métodos para conservar órganos y tejidos
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
JP4739207B2 (ja) * 2003-08-29 2011-08-03 ダイアックス コーポレーション ポリペグ化されたプロテアーゼインヒビター
WO2005021556A2 (en) 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
DK1854477T3 (en) 2006-03-16 2016-11-28 Dyax Corp Peptide inhibitors of plasma kallikrein for use in the treatment of eye disorders
US8467792B2 (en) * 2006-06-27 2013-06-18 Qualcomm Incorporated Method and apparatus for maintaining call continuity in wireless communication
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US20090105142A1 (en) * 2007-08-23 2009-04-23 Genzyme Corporation Treatment with kallikrein inhibitors
EP2350305A4 (en) 2008-10-22 2013-03-06 Dyax Corp COMBINATION TREATMENTS WITH PROTEASE BINDING PROTEINS FOR INFLAMMATORY DISEASES

Also Published As

Publication number Publication date
WO2007104541A2 (en) 2007-09-20
AU2007224643B2 (en) 2012-10-11
ES2601554T3 (es) 2017-02-15
US20150368359A1 (en) 2015-12-24
US9107928B2 (en) 2015-08-18
JP2012211194A (ja) 2012-11-01
SI2374472T1 (sl) 2018-11-30
LT2374472T (lt) 2018-09-25
HUE031701T2 (en) 2017-07-28
DK1854477T3 (en) 2016-11-28
CA2646285A1 (en) 2007-09-20
PL1854477T3 (pl) 2017-02-28
US20100273721A1 (en) 2010-10-28
HUE039108T2 (hu) 2018-12-28
PT1854477T (pt) 2016-11-10
LT1854477T (lt) 2016-12-12
AU2007224643A1 (en) 2007-09-20
JP5337493B2 (ja) 2013-11-06
JP2009529553A (ja) 2009-08-20
WO2007104541A3 (en) 2008-06-26
US20070270344A1 (en) 2007-11-22
ES2682646T3 (es) 2018-09-21
CA2646285C (en) 2020-04-28

Similar Documents

Publication Publication Date Title
LT2374472T (lt) Kompozicijos ir būdai oftalmologinių sutrikimų gydymui
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
ZA200700918B (en) Compositions and methods for treating eye disorders and conditions
EP2083862A4 (en) COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS
SI1881823T1 (sl) Sestavki in postopki za zdravljenje bolezni oäśesa
EP2083857A4 (en) METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA
GB2466912B (en) Compositions and methods for treating lysosomal disorders
IL198723A0 (en) Methods and compositions for therapeutic treatment
EP2069391A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING EYE DRYING
HK1149545A1 (en) Compositions and methods for treating ophthalmic diseases
EP2120994A4 (en) METHOD AND COMPOSITIONS FOR TREATING HYPOGLYKEMIC CONDITIONS
EP2077838A4 (en) METHODS FOR TREATING A-RELATED DISORDERS AND COMPOSITIONS THEREFOR
GB0718918D0 (en) Compositions and methods for treating skin conditions
HK1129596A1 (en) Methods and compositions for treating disease
PL2374472T3 (pl) Kompozycje i sposoby leczenia zaburzeń okulistycznych
EP1993612A4 (en) COMPOSITIONS AND METHODS FOR TREATING COGNITIVE INTERFERENCE
ZA201001779B (en) Compositions and methods for treating collagen-mediated diseases